|
|
Notice: Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Environmental Impact
Considerations Federal Register: January 5, 2010 (Volume 75, Number 2)
Page 379-382
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
February 4, 2010.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or e-mailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0322.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-3792,
Elizabeth.Berbakos@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Environmental Impact Considerations--21 CFR Part 25--OMB Control Number
0910-0322)--Extension
FDA is requesting OMB approval for the reporting requirements
contained in the FDA regulation ``Environmental Impact
Considerations.''
The National Environmental Policy Act (NEPA) (42 U.S.C. 4321-4347),
states national environmental objectives and imposes upon each Federal
agency the duty to consider the environmental effects of its actions.
Section 102(2)(C) of NEPA requires the preparation of an environmental
impact statement (EIS) for every major Federal action that will
significantly affect the quality of the human environment.
FDA's NEPA regulations are in part 25 (21 CFR part 25). All
applications or petitions requesting agency action require the
submission of a claim for a categorical exclusion or an environmental
assessment (EA). A categorical exclusion applies to certain classes of
FDA-regulated actions that usually have little or no potential to cause
significant environmental effects and are excluded from the
requirements to prepare an EA or EIS. Section 25.15(a) and (d)
specifies the procedures for submitting to FDA a claim for a
categorical exclusion. Extraordinary circumstances (Sec. 25.21), which
may result in significant environmental impacts, may exist for some
actions that are usually categorically excluded. An EA provides
information that is used to determine whether an FDA action could
result in a significant environmental impact. Section 25.40(a) and (c)
specifies the content requirements for EAs for nonexcluded actions.
This collection of information is used by FDA to assess the
environmental impact of agency actions and to ensure that the public is
informed of environmental analyses. Firms wishing to manufacture and
market substances regulated under statutes for which FDA is responsible
must, in most instances, submit applications requesting approval.
Environmental information must be included in such applications for the
purpose of determining whether the proposed action may have a
significant impact on the environment. Where significant adverse
effects cannot be avoided, the agency uses the submitted information as
the basis for
[[Page 380]]
preparing and circulating to the public an EIS, made available through
a Federal Register document also filed for comment at the Environmental
Protection Agency. The final EIS, including the comments received, is
reviewed by the agency to weigh environmental costs and benefits in
determining whether to pursue the proposed action or some alternative
that would reduce expected environmental impact.
Any final EIS would contain additional information gathered by the
agency after the publication of the draft EIS, a copy of or a summary
of the comments received on the draft EIS, and the agency's responses
to the comments, including any revisions resulting from the comments or
other information. When the agency finds that no significant
environmental effects are expected, the agency prepares a finding of no
significant impact (FONSI).
Estimated Annual Reporting Burden for Human Drugs (Including Biologics
in the Center for Devices and Radiological Health)
Under Sec. 312.23(a)(7)(iv)(e) (21 CFR 312.23(a)(7)(iv)(e)), 21
CFR 314.50(d)(1)(iii), and 21 CFR 314.94(a)(9)(i), each investigational
new drug application (IND), new drug application (NDA), and abbreviated
new drug application (ANDA) must contain a claim for categorical
exclusion under Sec. 25.30 or Sec. 25.31 or an EA under Sec. 25.40.
In 2008, FDA received 2,550 INDs from 2,026 sponsors; 106 NDAs from 88
applicants; 2,856 supplements to NDAs from 615 applicants; 13 biologics
license applications (BLAs) from 9 applicants; 206 supplements to BLAs
from 64 applicants; 835 ANDAs from 165 applicants; and 4,143
supplements to ANDAs from 224 applicants. FDA estimates that it
receives approximately 10,689 claims for categorical exclusions as
required under Sec. 25.15(a) and (d), and 20 EAs as required under
Sec. 25.40(a) and (c). Based on information provided by the
pharmaceutical industry, FDA estimates that it takes sponsors or
applicants approximately 8 hours to prepare a claim for a categorical
exclusion and approximately 3,400 hours to prepare an EA.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden for Human Drugs\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
25.15(a) and 3,171 3.37 10,686 8 85,488
(d)
----------------------------------------------------------------------------------------------------------------
25.40(a) and 20 1 20 3,400 68,000
(c)
----------------------------------------------------------------------------------------------------------------
Total 153,488
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Estimated Annual Reporting Burden for Human Foods
Under 21 CFR 71.1, 171.1, 170.39, and 170.100, food additive
petitions, color additive petitions, requests for exemption from
regulation as a food additive, and submission of a food contact
notification for a food contact substance must contain either a claim
of categorical exclusion under Sec. 25.30 or Sec. 25.32, or an EA
under Sec. 25.40. In 2008, FDA received 112 industry submissions. FDA
received an annual average of 67 claims of categorical exclusions as
required under Sec. 25.15(a) and (d), and 45 EAs as required under
Sec. 25.40(a) and (c). FDA estimates that, on average, it takes
petitioners, notifiers, or requestors approximately 3 hours to prepare
a claim of categorical exclusion and approximately 210 hours to prepare
an EA.
Table 2.--Estimated Annual Reporting Burden for Human Foods\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency per Total Annual Hours per
21 CFR Section Respondents Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
25.15(a) and (d) 40 1.7 68 3 204
--------------------------------------------------------------------------------------------------------------------------------------------------------
25.40(a) and (c) 24 1.9 45 210 9,450
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 9,654
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Estimated Annual Reporting Burden for Medical Devices
Under 21 CFR 814.20(b)(11), premarket approvals (PMAs) (original
PMAs and supplements) must contain a claim for categorical exclusion
under Sec. 25.30 or Sec. 25.34 or an environmental assessment under
Sec. 25.40. In 2008, FDA received approximately 39 claims (original
PMAs and supplements) for categorical exclusions as required under
Sec. 25.15(a) and (d), and 0 EAs as required under Sec. 25.40(a) and
(c). Based on information provided by less than 10 sponsors, FDA
estimates that it takes approximately 6 hours to prepare a claim for a
categorical exclusion and an unknown number of hours to prepare an EA.
[[Page 381]]
Table 3.--Estimated Annual Reporting Burden for Medical Devices\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
25.15(a) and 39 1 39 6 234
(d)
----------------------------------------------------------------------------------------------------------------
25.40(a) and 1 1 1 1 1
(c)
----------------------------------------------------------------------------------------------------------------
Total 235
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Estimated Annual Reporting Burden for Biological Products in the Center
for Biologics Evaluation and Research
Under Sec. 312.23(a)(7)(iv)(e) and 21 CFR 601.2(a), IND and BLAs
must contain a claim for categorical exclusion under Sec. 25.30 or
Sec. 25.31 or an EA under Sec. 25.40. In 2008, FDA received 245 INDs
from 180 sponsors; 28 BLAs from 13 applicants; and 972 BLA supplements
to license applications from 173 applicants. FDA estimates that
approximately 10 percent of these supplements would be submitted with a
claim for categorical exclusion or an EA.
FDA estimates that it received approximately 370 claims for
categorical exclusion as required under Sec. 25.15(a) and (d), and 2
EAs as required under Sec. 25.40(a) and (c). Based on information
provided by industry, FDA estimates that it takes sponsors and
applicants approximately 8 hours to prepare a claim for categorical
exclusion and approximately 3,400 hours to prepare an EA for a
biological product.
Table 4.--Estimated Annual Reporting Burden for Biological Products\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
25.15(a) and 210 1.76 370 8 2,960
(d)
----------------------------------------------------------------------------------------------------------------
25.40(a) and 2 1 2 3,400 6,800
(c)
----------------------------------------------------------------------------------------------------------------
Total 9,760
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Estimated Annual Reporting Burden for Animal Drugs
Under 21 CFR 514.1(b)(14), new animal drug applications (NADAs) and
abbreviated new animal drug applications (ANADAs); Sec. 514.8(a)(1)
supplemental NADAs and ANADAs; Sec. 511.1(b)(10) investigational new
animal drug applications (INADs); and Sec. 571.1(c) food additive
petitions must contain a claim for categorical exclusion under Sec.
25.30 or Sec. 25.33 or an EA under Sec. 25.40. In 2008, FDA's Center
for Veterinary Medicine has received approximately 676 claims for
categorical exclusion as required under Sec. 25.15(a) and (d), and 8
EAs as required under Sec. 25.40(a) and (c). FDA estimates that it
takes sponsors/applicants approximately 5 hours to prepare a claim for
a categorical exclusion and an average of 2,160 hours to prepare an EA.
Table 5.--Estimated Annual Reporting Burden for Animal Drugs\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency per Total Annual Hours per
21 CFR Section Respondents Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
25.15(a) and (d) 65 10.4 676 5 3,380
--------------------------------------------------------------------------------------------------------------------------------------------------------
25.40(a) and (c) 6 1.3 8 2,160 17,280
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 20,660
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Table 6.--Combined Estimated Annual Total Burden Hours for All Centers
------------------------------------------------------------------------
------------------------------------------------------------------------
Total 193,797
------------------------------------------------------------------------
[[Page 382]]
In the Federal Register of September 9, 2009 (74 FR 46430), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
Dated: December 23, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-31199 Filed 1-4-10; 8:45 am]
BILLING CODE 4160-01-S |